LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma

Christian Vogelberg (Dresden, Germany), Christian Vogelberg, István Laki, Olaf Schmidt, Eckard Hamelmann, Georges El Azzi, Michael Engel, Petra Moroni-Zentgraf, Helen Finnigan, Mark Vandewalker

Source: International Congress 2016 – Living with asthma around the globe
Session: Living with asthma around the globe
Session type: Thematic Poster
Number: 4399
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Christian Vogelberg (Dresden, Germany), Christian Vogelberg, István Laki, Olaf Schmidt, Eckard Hamelmann, Georges El Azzi, Michael Engel, Petra Moroni-Zentgraf, Helen Finnigan, Mark Vandewalker. LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma. Eur Respir J 2016; 48: Suppl. 60, 4399

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: Once-daily tiotropium Respimat® add-on therapy improves lung function in children with moderate symptomatic asthma
Source: International Congress 2016 – Living with asthma around the globe
Year: 2016


Tiotropium Respimat® add-on therapy in children with symptomatic asthma
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015


Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015


Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014

Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015


Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013


Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015


Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014

The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


LATE-BREAKING ABSTRACT: Outcome of withdrawal of one inhaler in COPD patients received combined ICS/LABA and LAMA
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014


Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014